Clinical Trial

Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period.
Protocol Amendment History 2 changes
notable Trial sites expanded: 160 -> 165 locations 2026-07-14
notable Trial sites expanded: 154 -> 159 locations 2026-06-05
Trial Details
NCT Number NCT05943535
Lead Sponsor United Therapeutics
Conditions Progressive Pulmonary Fibrosis, Interstitial Lung Disease
Enrollment 698 participants
Start Date 2023-10-30
Primary Completion 2027-11 (estimated)
Study Completion 2027-11 (estimated)
Updated on ClinicalTrials.gov 2026-07-13